Sanuwave pays off $6.3M Celularity note for $2.075M, extends SEPA merger deadline to June 30

SANUWAVE Health, Inc.

Paid $2.075 million to settle and extinguish a $6.3 million note and interest owed to Celularity from the 2020 UltraMist acquisition.
Withdrew Nasdaq listing application due to bid price requirement; submitted application to Cboe BZX Exchange, currently under review.
Extended SEPA merger outside date to June 30, 2024; Sanuwave received unilateral right to terminate the merger agreement at any time.
Reaffirmed FY2024 revenue guidance above $30 million (50% growth) and Q2 2024 revenue growth of 45-55% versus Q2 2023.
Capital raise from longtime shareholders funded the debt settlement; company believes it is sufficiently funded for remainder of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.